French Ask Bial For More Preclinical Data On FAAH Inhibitor

This article was originally published in SRA

26 Feb 2016
News

Ian Schofield @ScripIanS ian.schofield@informa.com

Executive Summary

The expert committee set up by the French medicines regulator ANSM to look into the preclinical data on Bial's FAAH inhibitor, BIA 10-2474, following the death of a volunteer and the hospitalization of several others during a Phase I study, has asked the Portuguese company for more data to support the committee's preliminary conclusion that the results of animal studies justified moving the compound into human trials¹.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS118559

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS118559

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

French Ask Bial For More Preclinical Data On FAAH Inhibitor

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert